Table 5 Treatment allocation for patients in the subgroup of patients with low-risk prostate cancer (Gleason ≤6, Stage 1, and PSA <10 ng/mL) and available data on biopsy tumour volume (n = 291), stratified by volume of prostate cancer

From: The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation

 

RadOnc (n, %)

Urologist alone (n, %)

Low-volume prostate cancer (≤2 positive cores)

No treatment

38 (62.3)

118 (88.1)

Any treatment

23 (37.7)

16 (11.9)

Radiation

16 (26.2)

<5

 EBRT

10 (16.4)

0

 Brachytherapya

6 (9.8)

<5

Surgery

7 (11.5)

11-15

High-volume prostate cancer (≥3 positive cores)

No treatment

17 (34.0)

33 (71.7)

Any treatment

33 (66.0)

13 (28.3)

Radiation

26 (52.0)

7 (15.3)

 EBRT

13 (26.0)

<5

 Brachytherapya

13 (26.0)

<5

Surgery

7 (14.0)

6 (13.0)

  1. Note: in order to comply with ICES privacy regulations, cell sizes smaller than 5 were suppressed. Where cells <5 would be calculable, the next smallest cell in the category was also suppressed
  2. EBRT external beam radiotherapy
  3. a Includes both low-dose rate (LDR) and high-dose rate (HDR) brachytherapy
Back to article page